www.mallinckrodt.com Open in urlscan Pro
146.214.96.228  Public Scan

Submitted URL: https://protect-us.mimecast.com/s/S-9vCKrmAyHMA20wUv01DV/
Effective URL: https://www.mallinckrodt.com/
Submission: On April 11 via manual from IN — Scanned from US

Form analysis 1 forms found in the DOM

GET /SearchBlock/Search

<form action="/SearchBlock/Search" method="get"> <input type="hidden" name="redirect" value="/corporate-search-results/">
  <input type="hidden" name="section" value="CorporateContent">
  <input name="searchText" type="search" placeholder="Search">
  <button type="submit">
    <i class="fa fa-search"></i>
  </button>
</form>

Text Content

Search

Font Size

 * About Us
    * About Us
        Back
        About Us
      * Executive Committee
          Back
          Executive Committee
        * Sigurdur (Siggi) Olafsson
        * Jason Goodson
        * Lisa French
        * Kassie Harrold
        * Henriette Nielsen
        * Bryan Reasons
        * Dr. Peter Richardson
        * Mark Tyndall
        * Stephen Welch
      * Select Senior Leaders
          Back
          Select Senior Leaders
        * Daniel Speciale
      * Board of Directors
          Back
          Board of Directors
        * Paul Bisaro
        * Sigurdur (Siggi) Olafsson
        * Daniel Celentano
        * Riad El-Dada
        * Neal Goldman
        * Karen Ling
        * Dr. Woodrow (Woody) Myers
        * Susan Silbermann
        * James Sulat
      * Scientific Advisory Council
      * Specialty Generics
      * COVID-19
      * Blog
      * Core Strengths
      * Diversity, Equity and Inclusion
      * MNK Recent Acquisitions
      * Our Story
      * Partnering
          Back
          Partnering
        * Suppliers
      * Patient Stories
      * 155th Anniversary

 * Products
 * Research
    * Research
        Back
        Research
      * Science & Technology
          Back
          Science & Technology
        * Pipeline
      * Research & Development
          Back
          Research & Development
        * Clinical Trials
        * Formulation & Drug Delivery Technologies
      * Medical Affairs
          Back
          Medical Affairs
        * Research Studies - IIR/ECR
        * Research & Educational Grants

 * Responsibility
    * Responsibility
        Back
        Responsibility
      * Community Outreach
          Back
          Community Outreach
        * Mallinckrodt Community Giving
        * Philanthropy Contacts
      * Corporate Compliance
      * Expanded Access Program for Investigational Products
      * Interactions with Health Care Professionals
      * Our Product Pricing
      * Quality, Environment, Health & Safety
      * Sustainability
      * Corporate Social Responsibility

 * Investor Relations
 * Contact Us
 * News & Media
 * Careers
    * Careers
        Back
        Careers
      * Who We Are
      * What We Do
      * Our Values & People
      * Where We Are
      * Search All Opportunities

Mallinckrodt uses cookies to improve and analyze site functionality. Some
aspects of the site may not function properly without cookies enabled. To learn
more about how we use cookies and how you can change your cookies settings,
please read our Privacy Policy. By continuing to browse the site, you are
agreeing to accept our use of cookies.

I Agree


SEEING COMPLEXITY
IN A NEW LIGHT 

Where others see complexity, we see value for patients and shareholders


SEEING VALUE
FOR PATIENTS

Where others see complexity, we see healthier lives


SEEING OPPORTUNITY
FOR SHAREHOLDERS

Where others see complexity, we see potential for growth

MANAGING COMPLEXITY.
IMPROVING LIVES.

For more than 150 years, Mallinckrodt has been advancing the fields of science
and medicine to improve the lives of people around the world.

About Us

BOLD PATH.
BRIGHTER FUTURE.

Grow your career, and become part of our legacy as we make a lasting difference
in the lives of patients.

Careers

A DIVERSE AND
GROWING PIPELINE.

Mallinckrodt is focused on developing innovative therapies and cutting-edge
technologies for patients with severe and critical conditions and has products
spanning all phases of clinical development.

Pipeline


MANAGING COMPLEXITY. IMPROVING LIVES.

NEWS & MEDIA

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX®
Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft
Versus Host Disease (cGvHD)
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult
Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF)
2023 Spring Clinical Meeting (SCM)
Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel
(Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for
Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual
Meeting
Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX®
Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft
Versus Host Disease (cGvHD)
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult
Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF)
2023 Spring Clinical Meeting (SCM)


COVID-19 RESOURCES

We are so grateful for all first responders, healthcare professionals and
essential employees' efforts in the battle against COVID-19. We believe in
listening to needs and delivering solutions and we are proud to join you in the
fight. We are doing a variety of things to make a difference.

Learn More


SUCCESSFUL COMPLETION OF FINANCIAL REORGANIZATION

Go to mnk.com/corporatefactsheet to learn more about Mallinckrodt and our path
forward.

Read More


A DIVERSE AND GROWING PIPELINE

Mallinckrodt is focused on developing innovative therapies and cutting-edge
technologies for patients with severe and critical conditions and has products
spanning all phases of clinical development.

View Our Pipeline


2020 CORPORATE SOCIAL RESPONSIBILITY REPORT RELEASED

Mallinckrodt releases its 2020 Corporate Social Responsibility Report
highlighting our continued commitment and ongoing progress.

Read More


INCLUSION & DIVERSITY

We are strengthened by the value we derive from the varied identities,
experiences, cultures and views of our employees.

Our Commitment


OUR PRODUCT PRICING

Our goal is to price our products responsibly while providing the best possible
healthcare for the greatest number of people.

Product Pricing


OUR PRODUCTS

Building on our heritage and distinctive capabilities, our world-class
development and formulation expertise bring medical solutions to the
marketplace.

Get Product Information

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and
other brands are trademarks of a Mallinckrodt company.© 2021 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc,
which is registered in Ireland as a public limited company with registration
number 522227 and has its registered office at College Business & Technology
Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.

UnitedHealthcare creates and publishes the Machine-Readable Files on behalf of
Mallinckrodt. To link to the Machine-Readable Files, please click on the URL
provided: transparency-in-coverage.uhc.com.

RESOURCES FOR:

 * Career Seekers
 * Investors
 * Suppliers

ABOUT MALLINCKRODT:

 * About Us
 * Home
 * Investor Relations
 * News & Media
 * Products
 * Research
 * Responsibility

OTHER LINKS:

 * Calif. Supply Chain Disclosure
 * Contact Us
 * Patents
 * Privacy Policy
 * Safety Data Sheets
 * Terms of Use
 * UK Modern Slavery Act Disclosure
 * UHC Transparency in Coverage
 * C-TPAT Statement of Support